These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

745 related articles for article (PubMed ID: 25894155)

  • 1. Efficacy of immunoadsorption to reduce donor-specific alloantibodies in kidney-transplant candidates.
    Rostaing L; Congy N; Aarnink A; Maggioni S; Allal A; Sallusto F; Game X; Kamar N
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():201-6. PubMed ID: 25894155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tandem hemodialysis and immunoadsorption to desensitize kidney transplant candidates.
    Rostaing L; Maggioni S; Hecht C; Hermelin M; Faudel E; Kamar N; Sallusto F; Doumerc N; Allal A
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():165-9. PubMed ID: 25894148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
    Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
    Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Transplantation in ABO- and HLA-Incompatible Living Kidney Transplant Patients: A Report on 12 Cases.
    Rostaing L; Karam B; Congy-Jolivet N; Hage V; Sallusto F; Esposito L; Doumerc N; Debiol B; Guilbeau-Frugier C; Game X; Allal A; Kamar N
    Ther Apher Dial; 2016 Oct; 20(5):507-516. PubMed ID: 27073167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
    Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
    Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
    Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desensitization in the Setting of HLA-Incompatible Kidney Transplant.
    Malvezzi P; Jouve T; Noble J; Rostaing L
    Exp Clin Transplant; 2018 Aug; 16(4):367-375. PubMed ID: 29863455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly Sensitized Patients: Miami Transplant Institute Experience.
    Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
    Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib in ABO-incompatible kidney transplant desensitization: a case report.
    Wong NL; O'Connell P; Chapman JR; Nankivell B; Kable K; Webster AC; Wong G
    Nephrology (Carlton); 2015 Mar; 20 Suppl 1():22-4. PubMed ID: 25807854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Living-Donor Kidney Transplant With Preformed Donor-Specific Antibodies.
    Itabashi Y; Aikawa A; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Arai T; Kawamura T; Hamasaki Y; Sakai K; Shishido S
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):43-49. PubMed ID: 30777522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of recipients of human leukocyte antigen incompatible kidney transplants who underwent desensitization at King Fahad Specialist Hospital, Dammam, Saudi Arabia.
    Idris MA; Hossain A; Muntasir MA; Marmi A; Aldajani AA; Aljamaan YM; Akhtar M; Housawi A
    Saudi J Kidney Dis Transpl; 2017; 28(3):499-506. PubMed ID: 28540885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
    Yuan XP; Wang CX; Gao W; Fu Q; He XS
    Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
    Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
    Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of antibody-mediated rejection including immunoadsorption during first year after renal transplantation--Clinical results and regulation of endothelial progenitor cells.
    Opgenoorth M; Wagner A; Passauer J; Hohenstein B; Hugo C
    Atheroscler Suppl; 2015 May; 18():67-73. PubMed ID: 25936307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Two Preemptive Post-transplant Desensitization Regimens Upon Renal Allograft Survival and DSA Elaboration.
    Kimball PM; McDougan FA; King A
    Clin Transpl; 2014; ():197-203. PubMed ID: 26281145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption.
    Becker LE; Siebert D; Süsal C; Opelz G; Leo A; Waldherr R; Macher-Goeppinger S; Schemmer P; Schaefer SM; Klein K; Beimler J; Zeier M; Schwenger V; Morath C
    Transplantation; 2015 Nov; 99(11):2364-71. PubMed ID: 25989497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of therapeutic apheresis in high immunologic risk renal transplantation: a review of current trends.
    Sanoff SL; Balogun RA; Lobo PL
    Semin Dial; 2012; 25(2):193-200. PubMed ID: 22321316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection.
    Dunn TB; Borja-Cacho D; Chinnakotla S; Finger E; Tamayo G; Verghese P; Kim Y; Manivel C; Kandaswamy R; Matas A; Pruett T; Noreen H; Krefting P; Maurer D
    Clin Transpl; 2011; ():381-7. PubMed ID: 22755435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desensitization in kidney transplantation: review and future perspectives.
    Abu Jawdeh BG; Cuffy MC; Alloway RR; Shields AR; Woodle ES
    Clin Transplant; 2014 Apr; 28(4):494-507. PubMed ID: 24621089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody.
    Moreno Gonzales MA; Gandhi MJ; Schinstock CA; Moore NA; Smith BH; Braaten NY; Stegall MD
    Transplantation; 2017 Jun; 101(6):1222-1227. PubMed ID: 27379560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.